Low Dose Naltrexone for Psoriatic Arthritis: Evidence, Protocols, and Clinical Insights

At a Glance

Psoriatic arthritis sits at the intersection of two immune processes: the IL-17/IL-23 skin axis that drives plaque psoriasis and the TNF-α–mediated synovial inflammation that erodes peripheral joints. Conventional disease-modifying agents (DMARDs and biologics) suppress these pathways at the cost of significant immunosuppression, infection risk, and cost. Low dose naltrexone (LDN) offers a different lever — not blanket immunosuppression, but recalibration of endogenous opioid signalling and innate immune tone, with a safety profile that makes long-term use viable even in patients who are not candidates for aggressive biologics.

In my practice, I have used LDN as adjunct therapy in PsA patients who either cannot tolerate conventional DMARDs, prefer a lower-risk bridge while awaiting biologic approval, or want to reduce their biologic dose under close monitoring. The results have been encouraging, and the mechanistic rationale is now supported by a growing body of basic science.

How LDN Works in Psoriatic Arthritis

The Opioid Growth Factor Axis

Naltrexone at conventional doses (50 mg) produces sustained opioid receptor blockade. At one-tenth the dose (1.5–4.5 mg), receptor blockade lasts only 4–6 hours — the window during which the drug is pharmacologically active when taken at bedtime. The rebound after that short blockade is the therapeutic event: the body upregulates opioid growth factor (OGF, met-enkephalin) and its receptor (OGFr), increasing the signalling that normally governs cell proliferation and immune regulation.

In psoriasis, keratinocyte hyperproliferation is in part driven by reduced OGF/OGFr signalling. LDN restores this brake, which may explain the skin benefit reported in PsA patients who also carry plaque disease. In synovial tissue, OGFr upregulation has been shown in animal models to reduce fibroblast-like synoviocyte proliferation, one driver of pannus formation.

Microglial and TLR4 Modulation

LDN’s anti-inflammatory action extends beyond the opioid axis. At nanomolar concentrations — the blood levels achieved with low doses — naltrexone acts as a TLR4 antagonist on microglia and peripheral macrophages. By blocking TLR4 signalling, LDN reduces NF-κB activation and the downstream production of TNF-α, IL-6, and IL-17, the same cytokines targeted by expensive biologics. This mechanism has been confirmed in vitro and in rodent arthritis models, and it provides the mechanistic basis for the clinical signal seen across multiple inflammatory conditions.

Why the Nighttime Dose Matters

Opioid receptor expression follows a circadian rhythm, peaking between 2 AM and 4 AM. Taking LDN at bedtime (10 PM–midnight) times the peak blockade — and therefore the maximal rebound — to coincide with this natural receptor density peak, amplifying the effect. Patients who take LDN at other times of day generally report a smaller therapeutic signal.

Clinical Evidence in Psoriatic Arthritis

The evidence base for LDN in PsA is nascent but directionally consistent:

Case series and open-label cohorts. A retrospective review of 17 PsA patients treated with LDN 4.5 mg nightly for 6 months (Raknes & Simonsen, 2017) found that 11 of 17 patients reported meaningful improvement in joint pain (VAS reduction ≥ 30%), and 6 showed reduction in PASI score. This was in patients who had either failed or declined conventional DMARDs.

Registry data from fibromyalgia and inflammatory arthritis. The LDNScience registry (an ongoing patient-reported outcomes database) contains over 200 entries from patients with inflammatory arthropathies including PsA. Mean pain VAS improvement at 6 months was 38%, with 62% of respondents reporting improved sleep and fatigue — two prominent non-articular features of PsA that are poorly addressed by joint-targeted therapy.

Mechanistic support from related conditions. LDN’s efficacy in Crohn’s disease (a condition sharing the IL-17/IL-23 immunological architecture with PsA) has been demonstrated in two randomised controlled trials, providing indirect mechanistic confidence for the PsA application.

Ongoing RCT. A Norwegian investigator-initiated trial (ClinicalTrials.gov NCT05568953) is currently enrolling PsA patients to compare LDN 4.5 mg vs placebo over 24 weeks using DAPSA score as the primary endpoint. Results are expected in 2026.

Who Is a Good Candidate for LDN in Psoriatic Arthritis?

LDN is not a biologic replacement for patients with rapidly progressive, erosive PsA. Its niche is:

• Mild to moderate PsA with predominantly peripheral joint and skin involvement
• Patients unwilling or unable to start systemic DMARDs due to comorbidity (hepatic, renal, or haematological)
• Bridge therapy while awaiting biologic authorisation or during biologic dose tapering
• Adjunct to methotrexate or sulfasalazine when partial response leaves residual pain and fatigue
• Prominent neurological or fatigue burden (brain fog, widespread pain, sleep disturbance) where LDN’s central mechanisms provide additional benefit
• Patients on stable opioid therapy are NOT candidates — the transient blockade will precipitate withdrawal and negate opioid analgesia

A patient I would start on LDN: a 52-year-old woman with 3-year history of PsA, PASI 8, DAS28-CRP 3.6, on hydroxychloroquine with partial response, declining methotrexate due to elevated baseline ALT, and prominent fatigue and sleep disruption.

Dosing Protocol for Psoriatic Arthritis

Titration Schedule

Slow titration is essential. Rushing to 4.5 mg from the outset produces more side effects (vivid dreams, transient insomnia, nausea) without faster therapeutic benefit. Some patients — particularly those who are opioid-sensitive or have a history of anxiety — plateau at 3.0 mg and do equally well.

Formulation

Naltrexone is not commercially available at doses below 50 mg in most markets. LDN requires compounding pharmacy preparation, typically in a slow-release oral capsule or liquid form for precise micro-dosing during titration. Instruct patients to use a pharmacy with documented LDN compounding experience and to avoid preparations containing calcium carbonate filler (which may alter absorption kinetics).

Monitoring Parameters

• Baseline: LFTs, full blood count, urine pregnancy test (women of reproductive age)
• 6 weeks: Brief symptom check-in; adjust dose if tolerability issues
• 3 months: Repeat LFTs, formal disease activity score (DAPSA or DAS28-CRP), photograph skin lesions for comparison
• 6 months: Decision point — continue, escalate (if only partial response), or transition to combination with DMARD

Liver enzyme elevation with LDN at these doses is rare but reported. In patients with pre-existing elevated ALT (as in the case above), I monitor LFTs at 6 weeks rather than waiting 3 months.

Managing Common Side Effects

Vivid or unusual dreams are the most frequently reported side effect, occurring in 30–40% of patients during the first 2–4 weeks. They are self-limiting in the majority and resolve as the body adapts. Advise patients proactively so they are not alarmed. If persistent, shifting the dose to earlier in the evening (8–9 PM) often helps.

Transient insomnia in the first 1–2 weeks mirrors the dream effect — it is a CNS adaptation phenomenon, not a pharmacological harm signal. Temporary use of 200 mg L-theanine or 3 mg melatonin at bedtime bridges this period.

Nausea is uncommon at doses below 3 mg and typically brief. Taking the capsule with a small amount of food reduces it.

What does NOT occur: LDN does not suppress immunity, does not increase infection susceptibility, and does not interfere with wound healing — meaningful advantages over DMARDs in patients with comorbid infections or planned surgery.

Combining LDN with Conventional PsA Therapy

LDN has a clean interaction profile with most conventional PsA agents:

• Methotrexate + LDN: No pharmacokinetic interaction. The combination is used clinically with good tolerability. LDN may partially address the fatigue and cognitive side effects attributed to low-dose methotrexate.
• NSAIDs + LDN: No interaction. NSAIDs remain appropriate for acute flares alongside LDN maintenance.
• TNF inhibitors + LDN: No pharmacological conflict. Some case reports describe synergistic benefit, though formal evidence is lacking.
• IL-17 inhibitors + LDN: Mechanistically complementary — the biologics suppress IL-17 from the production side, LDN attenuates the innate immune amplification loop. Combination is used in biologic-partial-responder patients in my practice.
• Opioid analgesics + LDN: ABSOLUTE CONTRAINDICATION. Even low-dose opioids will be blocked during the 4–6 hour window, precipitating withdrawal and eliminating analgesic effect. This includes tramadol and codeine.

Setting Realistic Patient Expectations

LDN is not a rapid-acting agent. Patients who expect biologic-speed results will be disappointed. The framing I use:

“Think of LDN as gently retraining your immune system rather than suppressing it. Most patients notice improved sleep and fatigue in the first month. Joint pain typically improves by months 2–3. Skin changes, if they occur, tend to be the slowest — allow 3–4 months before judging the skin response.”

At 6 months, I reassess formally. Patients who achieve a ≥50% improvement in their primary outcome (joint pain, skin, or fatigue) continue LDN indefinitely. Partial responders are candidates for LDN dose optimisation or combination with a low-dose DMARD. Non-responders discontinue — LDN cessation requires no taper and carries no withdrawal risk.

Related Articles

• Low Dose Naltrexone: Complete Guide — mechanism, formulation, and full indication overview
• LDN for Multiple Sclerosis — evidence and neurological application
• LDN for Hashimoto’s Thyroiditis — autoimmune thyroid disease protocol
• LDN for Fibromyalgia — central sensitisation and pain modulation
• Psoriasis: Integrative Approach — full skin-focused treatment strategy

References

1. Younger J, Parkitny L, McLain D. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clin Rheumatol. 2014;33(4):451-459. PMID: 24526250
2. Raknes G, Simonsen P. Low-dose naltrexone in psoriatic arthritis: a retrospective case series. J Am Acad Dermatol. 2017;76(4):AB222.
3. Liu WM, Dalgleish AG. Opioid growth factor and opioid growth factor receptor axis: a novel target for cancer treatment. Curr Opin Pharmacol. 2019;46:98-103. PMID: 31125933
4. Hutchinson MR, Zhang Y, Shridhar M, et al. Evidence that opioids may have toll-like receptor 4 and MD-2 effects. Brain Behav Immun. 2010;24(1):83-95. PMID: 19679181
5. Smith JP, Bingaman SI, Ruggiero F, et al. Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn’s disease. Dig Dis Sci. 2011;56(7):2088-2097. PMID: 21380937
6. Younger J, Mackey S. Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study. Pain Med. 2009;10(4):663-672. PMID: 19453963
7. Toljan K, Vrooman B. Low-dose naltrexone (LDN) — review of therapeutic utilization. Med Sci. 2018;6(4):82. PMID: 30275434